AU2024242849A1 - Method for detecting cell membrane protein - Google Patents

Method for detecting cell membrane protein

Info

Publication number
AU2024242849A1
AU2024242849A1 AU2024242849A AU2024242849A AU2024242849A1 AU 2024242849 A1 AU2024242849 A1 AU 2024242849A1 AU 2024242849 A AU2024242849 A AU 2024242849A AU 2024242849 A AU2024242849 A AU 2024242849A AU 2024242849 A1 AU2024242849 A1 AU 2024242849A1
Authority
AU
Australia
Prior art keywords
tissue
protein
antibody
removal
embedding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024242849A
Other languages
English (en)
Inventor
Takayoshi Ido
Fumiyoshi Okano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of AU2024242849A1 publication Critical patent/AU2024242849A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/36—Embedding or analogous mounting of samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2024242849A 2023-03-28 2024-03-27 Method for detecting cell membrane protein Pending AU2024242849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023050776 2023-03-28
JP2023-050776 2023-03-28
PCT/JP2024/012221 WO2024204325A1 (ja) 2023-03-28 2024-03-27 細胞膜タンパク質を検出する方法

Publications (1)

Publication Number Publication Date
AU2024242849A1 true AU2024242849A1 (en) 2025-09-25

Family

ID=92906670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024242849A Pending AU2024242849A1 (en) 2023-03-28 2024-03-27 Method for detecting cell membrane protein

Country Status (7)

Country Link
EP (1) EP4692791A1 (https=)
JP (1) JPWO2024204325A1 (https=)
KR (1) KR20250166224A (https=)
CN (1) CN120677381A (https=)
AU (1) AU2024242849A1 (https=)
MX (1) MX2025010250A (https=)
WO (1) WO2024204325A1 (https=)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE349010T1 (de) 2003-02-27 2007-01-15 Dako Denmark As Standard für immunhistochemie, immunzytologie und molekulare zytogenetika
US20060252025A1 (en) * 2004-12-30 2006-11-09 Ventana Medical Systems, Inc. Low temperature deparaffinization
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
US8067241B2 (en) 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
PL2876447T3 (pl) * 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109890417A (zh) 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物
AU2019242520B2 (en) 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US20220073641A1 (en) * 2018-12-28 2022-03-10 The University Of Tokyo Fusion protein of antibody that recognizes cancer cells and mutant streptavidin
JP2023050776A (ja) 2021-09-30 2023-04-11 パナソニックＩｐマネジメント株式会社 パネル装置

Also Published As

Publication number Publication date
CN120677381A (zh) 2025-09-19
EP4692791A1 (en) 2026-02-11
KR20250166224A (ko) 2025-11-27
JPWO2024204325A1 (https=) 2024-10-03
WO2024204325A1 (ja) 2024-10-03
MX2025010250A (es) 2025-10-01

Similar Documents

Publication Publication Date Title
Kabiraj et al. Principle and techniques of immunohistochemistry—a review
CN106415269B (zh) 直接免疫组织化学测定
CN110337588B (zh) 用于定量免疫组织化学的方法和系统
US8557602B2 (en) Method for detecting and distinguishing intrahepatic cholangiocarcinoma
EP2898329B1 (en) Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
CN103597089B (zh) 用于酶介导的信号放大的方法
AU2007291077B2 (en) Antibodies to an epitope of AGR2. assays and hybridomas
US20240077489A1 (en) Styryl phenols, derivatives and their use in methods of analyte detection
US9625461B2 (en) Method of detecting cancer using delta-catenin
KR20190045200A (ko) 방광암용 바이오마커로서의 케라틴 17
JP2021517242A (ja) Ｍａｇｅａ４を検出する方法
Flores-Maldonado et al. A low cost antibody signal enhancer improves immunolabeling in cell culture, primate brain and human cancer biopsy
US20210048432A1 (en) Direct immunohistochemistry and immunocytochemistry methods
US8486657B2 (en) Anti-preproprotein and anti-preprotein antibodies as immunohistochemical markers
AU2024242849A1 (en) Method for detecting cell membrane protein
EP2373997A1 (en) Method for evaluating pre-treatment
Lohse et al. Improved catalyzed reporter deposition, iCARD
CA3285382A1 (en) Method for detecting cell membrane protein
US5369002A (en) Method of detecting injured nuclear DNA
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
US20250321232A1 (en) Chromogenic multiplexing methods and systems for identifying a cancer of unknown primary origin
Singh et al. Immunohistochemistry, A Golden Technique for Disease Diagnosis: A Review
CN116539894A (zh) Capg在制备病理性心肌肥厚检测试剂中的应用
JP2021519284A (ja) 治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ
Steilen-Gimbel et al. Simultaneous Multicolor-FISH and Immunocyto-chemical Analysis of Fresh Tumor Material